Table 2.
Comparison of demographic and clinical features between MRSA bacteremic patients with favorable and unfavorable final clinical responsesa
| Variables | Unfavorable outcomes (n=67) | Favorable outcomes (n=79) | p-value |
|---|---|---|---|
| Male gender, n (%) | 37 (55.2) | 52 (65.8) | 0.23 |
| Age median (range), years | 72 (61–81) | 67 (57–79) | 0.12 |
| Community-acquired, n (%) | 1 (1.5) | 11 (13.9) | 0.01 |
| Hospital-acquired, n (%) | 55 (82.1) | 56 (70.9) | 0.12 |
| Health care-associated, n (%) | 11 (16.4) | 12 (15.2) | >0.99 |
| Duration of therapy, median (range), days | 7 (4–13) | 14 (9–17) | <0.01 |
| Comorbidities and disease severity,b n (%) | |||
| Coronary artery disease | 23 (34.3) | 14 (17.7) | 0.02 |
| Diabetes mellitus | 32 (47.8) | 37 (46.8) | >0.99 |
| Hypertension | 36 (53.7) | 36 (45.6) | 0.41 |
| Solid tumor | 12(17.9) | 16 (20.3) | 0.83 |
| Hematological malignancy | 1 (1.5) | 1 (1.3) | >0.99 |
| Liver cirrhosis | 10 (14.9) | 10 (12.7) | 0.81 |
| COPD | 12 (7.9) | 11 (13.9) | 0.65 |
| Congestive heart failure | 16 (23.9) | 12 (15.2) | 0.21 |
| eGFR, median (range), mL/min | 65 (5–95) | 67 (5–95) | 0.67 |
| eGFR <60 mL/min/1.73 m2 | 17 (25.4) | 14 (17.7) | 0.31 |
| Prosthetic device implantation | 23 (34.3) | 19 (24.1) | 0.20 |
| Pittsburgh bacteremia score ≥4 | 40 (59.7) | 10 (12.7) | <0.01 |
| Source of bacteremia,c n (%) | |||
| Catheter-related infection | 16 (23.9) | 16 (20.3) | 0.69 |
| Bone and joint infection | 8 (11.9) | 19 (24.1) | 0.09 |
| IE | 10 (14.9) | 3 (3.8) | 0.02 |
| SSTI | 7 (10.4) | 18 (22.8) | 0.08 |
| IAI | 3 (4.5) | 5 (6.3) | 0.73 |
| UTI | 0 | 2 (2.5) | 0.50 |
| PN | 14 (20.9) | 8 (10.1) | 0.10 |
| No identified focus of infection | 9 (13.4) | 8 (10.1) | 0.61 |
| Teicoplanin MIC for MRSA isolates and treatment with teicoplanin maintenance dose | |||
| MICs of teicoplanin, median (range), mg/L | 1.5 (1–1.5) | 1 (1–1.5) | 0.23 |
| HI, n (%) | 7 (10.4) | 37 (46.8) | <0.01 |
| Teicoplanin MICs ≥1.5 mg/L, n (%) | 35 (52.2) | 35 (44.3) | 0.41 |
| ST for isolates with teicoplanin MICs <1.5 mg/L, n (%) | 27 (40.3) | 26 (32.9) | 0.39 |
| ST for isolates with teicoplanin MICs ≥1.5 mg/L, n (%) | 33 (49.3) | 16 (20.3) | <0.01 |
| HI for isolates with teicoplanin MICs <1.5 mg/L, n (%) | 5 (7.5) | 18 (22.8) | 0.01 |
| HI for isolates with teicoplanin MICs ≥1.5 mg/L, n (%) | 2 (3.0) | 19 (24.1) | <0.01 |
Notes: There was adequate goodness of fit (Hosmer and Lemeshow test, χ2=0.51, p=0.92). Receiver operating characteristic analysis indicated that predictive performance of logistic regression model was adequate (area under the curve =0.84).
Evaluation at the completion of teicoplanin therapy.
At sampling blood for culture.
A patient might have >1 bacteremia source.
Abbreviations: COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; HI, high-dose regimen group; IAI, intra-abdominal infection; IE, infective endocarditis; MIC, minimum inhibitory concentration; MRSA, methicillin-resistant Staphylococcus aureus; PN, pneumonia; SSTI, skin and soft tissue infection; UTI, urinary tract infection; ST, standard-dose regimen group; HI, high-dose regimen group.